Literature DB >> 33854216

Relugolix - new treatment for uterine fibroid-related heavy bleeding.

Donna D Baird1, Quaker E Harmon2.   

Abstract

Entities:  

Year:  2021        PMID： 33854216     DOI： 10.1038/s41574-021-00493-2

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  2 in total

1.  A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years.

Authors:  D D Baird; T M Saldana; D L Shore; M C Hill; J M Schectman
Journal:  Hum Reprod       Date:  2015-09-25       Impact factor: 6.918

2.  The natural history of uterine leiomyomas: light and electron microscopic studies of fibroid phases, interstitial ischemia, inanosis, and reclamation.

Authors:  Gordon P Flake; Alicia B Moore; Deloris Sutton; Grace E Kissling; John Horton; Benita Wicker; David Walmer; Stanley J Robboy; Darlene Dixon
Journal:  Obstet Gynecol Int       Date:  2013-11-21
  2 in total
  2 in total

Review 1.  Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.

Authors:  Mohamed Ali; Mohamed Raslan; Michał Ciebiera; Kornelia Zaręba; Ayman Al-Hendy
Journal:  Expert Opin Drug Saf       Date:  2021-10-20       Impact factor: 4.250

2.  An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma.

Authors:  Liying Xing; Ya-Nan Liu; Hongye Yao; Tingting Wang; Fuchen Xie; Shunbin Luo; Pingping Luo; Shengling Tang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.